Aenitis Technologies

Acoustic cell processing technology for cell and gene therapy manufacturing

Paris · Founded 2015 · $16.9M raised

Headquarters
Paris
Employees
11–50
Founded
2015
Business Model
B2B
Website
aenitis.fr
Total Funding
$16.9M
Last Round
$16.9M Venture RoundOct 2024
Rounds
1

About

Aenitis Technologies is a Paris-based deeptech biotech company founded in 2014 by pioneers of acoustic levitation and fluid mechanics alongside biotech entrepreneur Emmanuel Vincent (CEO). The company develops and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. Using controlled ultrasonic waves, Aenitis' platform enables the contact-free, continuous manipulation of cells in fully sterile closed systems — supporting key unit operations including cell sorting, isolation, concentration, and washing at millifluidic scale (tens of milliliters per minute) without altering cell viability or functionality. Its flagship product, Mitis, is used across research, clinical, and industrial applications. The Modular Type Package (MTP) approach enables flexible integration of acoustic cell processing steps into existing GMP bioprocess workflows through co-development, licensing, or custom consumable integration. Aenitis has received support from the European Commission, the French Government, the European Investment Bank, and leading investors including Seventure Partners.

Summary

Aenitis Technologies is a Biotech company based in Paris, founded in 2015. It has raised $16.9M in total across 1 round, most recently a $16.9M Venture Round round in Oct 2024. Investors include European Innovation Council Fund and Seventure Partners.

Sign up to view the funding chart

Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.

Funding History

Venture RoundVenture RoundOct 2024
$16.9M

Investors

Similar Companies